A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Sun Yat-sen University
Pfizer
Institut du Cancer de Montpellier - Val d'Aurelle
Universitätsmedizin Mannheim
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Institut Bergonié
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer
Servicio de Salud Metropolitano Sur Oriente
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center